Imricor Q1 CY25 Quarterly Activities Report and Appendix 4C

Open PDF
Stock Imricor Medical Systems Inc (IMR.ASX)
Release Time 23 Apr 2025, 10:19 a.m.
Price Sensitive Yes
 Imricor Q1 CY25 Quarterly Activities Report and Appendix 4C
Key Points
  • Successful submission of 2nd Premarket Approval (PMA) Module to US FDA
  • CE Mark approval received for 2nd generation Vision-MR Ablation Catheter
  • Ethics approval received at Amsterdam University Medical Centre to commence VISABL-VT pivotal trial
Full Summary

Imricor Medical Systems, Inc. (ASX: IMR) released its Appendix 4C Quarterly Cash Flow Report for the period ended 31 March 2025 and provided an update on its operational performance. Key highlights include successful submission of the 2nd Premarket Approval (PMA) Module to the US FDA, CE Mark approval for the 2nd generation Vision-MR Ablation Catheter under the new European Medical Device Regulation (MDR), and ethics approval received at Amsterdam University Medical Centre (AUMC) to commence the VISABL-VT pivotal trial. The company also reported that the AUMC medical team completed on-site training at Imricor's iCMR Design Centre in Minneapolis in preparation for the world's first MRI-guided ventricular ablations, and that the first-in-man ventricular ablation guided by real-time iCMR was subsequently performed at AUMC. Imricor's European sales team rebuild is progressing, with four additional hires joining during the quarter or scheduled to join in the near future, and the company has hired its first capital sales managers in the US in preparation for the US commercial launch. Imricor also attended industry conferences, including the Gulf Arrhythmia Congress in Dubai and the EHRA Congress in Vienna. Financially, the company reported consumables revenue of $104k, up 385% on Q1 2024, and total revenue of $132k. Cash receipts were $199k, up 83% on the prior corresponding period, and operating cash outflows were $4.6m, down 3% on the prior corresponding period. Imricor completed a placement raising A$70.0 million and ended the quarter with a cash balance of US$53.9m (~A$85.5m).

Guidance

Imricor did not provide any high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics in the announcement.

Outlook

Imricor did not provide any forward-looking outlook in the announcement.